FDA Brief

Warning letters Drugs

FDA warning letter to

Korean Aesthetic dba Korean Fillers

High riskIssued Nov 3, 2025Posted Nov 5, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Korean Fillers that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.

What happened

FDA reviewed www.koreanfillers.com and found the site offering injectable botulinum toxin products, including Meditoxin Botulinum Toxin, Cosmetics Medi 2, and Meditoxin Botulinum Toxin 200U, for sale to U.S. consumers. FDA said the site claimed the products treat conditions such as essential blepharospasm, cerebral palsy, and post-stroke upper limb spasticity, which shows they are drugs. FDA said there are no approved applications for these products and that their labeling lacks adequate directions for use, making them unapproved and misbranded.

What FDA found

  1. The website offers botulinum toxin drug products for sale in the U.S. without FDA-approved applications.

    section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]
  2. The products are misbranded because their labeling does not give adequate directions for safe use by a layperson.

    section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]
  3. By offering the prescription drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.

    section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
  4. FDA treats the products as drugs and new drugs because they are intended to treat medical conditions and are not generally recognized as safe and effective.

    sections 201(g) and 201(p) of the FD&C Act [21 U.S.C. §§ 321(g), 321(p)]

What FDA wants

FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to correct the violations and prevent recurrence.

Who should pay attention

  • companies selling injectable cosmetic or therapeutic drugs online
  • clinics and consumers buying imported botulinum toxin products
  • distributors and websites offering foreign drug products in the U.S.

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk